PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
PD-L1
Papillary thyroid cancer
lymphocytic thyroiditis
programmed cell death ligand 1
tumour microenvironment
Journal
Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
21
06
2019
revised:
02
11
2019
accepted:
10
11
2019
pubmed:
29
2
2020
medline:
15
12
2020
entrez:
29
2
2020
Statut:
ppublish
Résumé
The impact of concurrent autoimmune thyroid disease on the tumour microenvironment and disease progression in papillary thyroid cancer (PTC) is not well understood. Studies evaluating the programmed cell death ligand 1 (PD-L1) tumour expression in PTC have shown variable results, and the effect of lymphocytic thyroiditis (LT) on tumour PD-L1 expression has not been adequately assessed. The main aim of this study was to determine expression of PD-L1 in PTC with and without LT. We examined 81 PTC cases; 28.5% of all reviewed PTC had presence of LT. In PTC specimens without LT, tumour PD-L1 expression was significantly lower compared to PD-L1 expression in PTC with LT, 6.9% vs 39.1%, respectively. Expression of PD-L1 did not differ with PTC stage, even when sub-categorised according to the presence and absence of LT. Utility of PD- L1 expression as a prognostic marker in thyroid cancer needs to be interpreted with caution.
Identifiants
pubmed: 32107082
pii: S0031-3025(20)30457-8
doi: 10.1016/j.pathol.2019.11.007
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
318-322Informations de copyright
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.